NCT05878834

Efficacy and Safety of Beta-glucan Supplement in Chronic Obstructive Pulmonary Disease Patients

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Chulalongkorn University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objectives of this study are to evaluate Efficacy and safety of beta-glucan supplement in chronic obstructive pulmonary disease patients.

Detailed description

There are 72 patients in this study. They are randomly divided into 2 groups which are beta-glucan supplement group and placebo group. The supplement will be taken 1 capsule/day for 12 weeks. Forced expiratory volume in 1 second/Forced vital capacity, Modified Medical Research Council Dyspnea Score, Breathlessness, Cough, and Sputum Scale, 6 Minute Walk Test, Diffusing capacity for carbon monoxide, Tumor necrosis factor alpha, Interleukin-6, C-reactive protein, glutathione, aspartate transaminase, alanine transaminase, alkaline phosphatase, creatinine, and blood urea nitrogen are assessed before and after taking supplement 6 and 12 weeks.

Conditions

• Chronic Obstructive Pulmonary Disease Patients

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Beta-glucan supplement group	Take 1 capsule 1 time per day for 12 weeks.
DIETARY_SUPPLEMENT	Placebo group	Take 1 capsule 1 time per day for 12 weeks.

Timeline

• Start date: 2023-05-25
• Primary completion: 2023-11-30
• Completion: 2023-12-20
• First posted: 2023-05-26
• Last updated: 2023-05-30